Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock